Jon Napitupulu

aTyr Pharma released interim Phase 2 data for efzofitimod, a potential treatment for systemic sclerosis-related interstitial lung disease (SSc-ILD)....

Corvus Pharmaceuticals released interim Phase 1 clinical trial data for soquelitinib, an oral ITK inhibitor, in patients with moderate...

Biomerica’s inFoods IBS test, a personalized dietary therapy for Irritable Bowel Syndrome (IBS), demonstrated statistically significant improvement in patient...

Dyne Therapeutics announced preclinical data showing its drug candidate, DYNE-302, improved muscle function in a mouse model of facioscapulohumeral...

Rectify Pharmaceuticals presented data on RTY-822, a positive functional modulator (PFM) targeting the ABCC6 membrane transporter, at the 2025...

Actuate Therapeutics’ Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) achieved its primary endpoint, demonstrating a statistically significant...

ImPact Biotech announced interim Phase 3 trial results for Padeliporfin VTP, a treatment for low-grade upper tract urothelial cancer...

A Teva-sponsored study reveals significant care gaps for tardive dyskinesia (TD) among long-term care (LTC) residents. More than half...

HUTCHMED announced positive interim results from its SACHI Phase III study, showing that the combination of savolitinib and osimertinib...

Allogene Therapeutics presented positive Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic CAR T therapy, for...